PRNAF Alterity Therapeutics Ltd (PK)

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2023

 

Alterity Therapeutics Limited

(Name of Registrant)

 

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒       Form 40-F  ☐

 

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

 

 

 

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

 

The following exhibits are submitted:

 

99.1

Trading Halt

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Alterity Therapeutics Limited
	By:	/s/ Geoffrey P. Kempler
		Geoffrey P. Kempler
		Chairman

 

Date: November 20, 2023

  

 

2

Exhibit 99.1

 

 

Market Announcement

 

20 November 2023

 

 

Alterity Therapeutics Limited (ASX: ATH) – Trading Halt

 

Description

 

The securities of Alterity Therapeutics Limited (‘ATH’) will be placed in trading halt at the request of ATH, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 22 November 2023 or when the announcement is released to the market.

 

Issued by

 

Melissa Kostopoulos

Senior Adviser, Listings Compliance

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

20 November 2023	Market Announcement 1/1
ASX Limited	ASX Customer Service Centre 131 279 | asx.com.au

 

 

 

20 November 2023

 

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)

ASX Compliance Pty Ltd

Level 50, South Tower, Rialto

525 Collins St

Melbourne VIC 3000

 

By email:

tradinghaltsmelbourne@asx.com.au

 

Dear Melissa

 

Request for a trading halt – Alterity Therapeutics Limited

 

In accordance with ASX Listing Rule 17.1, Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (the Company) requests that its securities be placed into an immediate trading halt pending an announcement in relation to a capital raise.

 

The Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on Wednesday, 22 November 2023, whichever is the earlier.

 

The Company is not aware of any reason why this trading halt request should not be granted or of any other information necessary to inform the market about the trading halt.

 

Please contact me if you require any further information.

Yours sincerely

 

Phillip Hains
Company Secretary

 

 

 

 

 

 

Alterity Therapeutics Limited ABN 37 080 699 065

Level 14, 350 Collins Street, Melbourne, VIC 3000 Australia

T: +61 (0)3 9349 4906 | www.alteritytherapeutics.com

 

---